Janus kinase 3: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tags: mobile edit mobile web edit
 
CSV import
 
Line 1: Line 1:
'''Janus kinase 3''' ('''JAK3''') is a [[protein]] that in humans is encoded by the ''JAK3'' [[gene]]. It is a member of the [[Janus kinase]] family and plays a critical role in the [[JAK-STAT signaling pathway]], which is involved in the control of [[cell growth]], [[cell differentiation]], and [[immune system]] function. JAK3 specifically is essential for the signaling of [[cytokines]] that bind to the Type I and Type III [[receptor]] families.
{{DISPLAYTITLE:Janus Kinase 3}}
 
== Janus Kinase 3 ==
[[File:JAK3_signal_transduction.jpg|thumb|right|Diagram of JAK3 signal transduction pathway]]
 
'''Janus kinase 3''' ('''JAK3''') is a member of the [[Janus kinase]] family of intracellular, non-receptor [[tyrosine kinases]]. JAK3 is primarily expressed in [[hematopoietic cells]] and plays a crucial role in the signaling pathways of various [[cytokine receptors]].
 
== Structure ==
JAK3, like other members of the Janus kinase family, contains several important domains: a [[Ferm domain]], an SH2-like domain, a pseudokinase domain, and a kinase domain. The kinase domain is responsible for the enzyme's catalytic activity, while the pseudokinase domain regulates the kinase activity.


== Function ==
== Function ==
JAK3 is predominantly expressed in [[immune cells]], including [[T cells]], [[B cells]], and [[natural killer cells]]. It is involved in the signaling pathway of [[cytokines]] such as [[interleukin-2]], [[interleukin-4]], [[interleukin-7]], [[interleukin-9]], [[interleukin-15]], and [[interleukin-21]], which are crucial for [[lymphocyte]] development, function, and homeostasis. Activation of JAK3 leads to the phosphorylation and activation of [[Signal Transducer and Activator of Transcription|STATs (Signal Transducers and Activators of Transcription)]], which then translocate to the nucleus to effect [[gene expression]].
JAK3 is involved in the signaling of type I and type II cytokine receptors, which include receptors for [[interleukins]] such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. These cytokines are critical for the development and function of the [[immune system]]. JAK3 associates with the common gamma chain (_c) of these cytokine receptors and, upon cytokine binding, becomes activated through trans-phosphorylation.
 
== Signal Transduction ==
Upon activation, JAK3 phosphorylates specific tyrosine residues on the receptor, creating docking sites for [[signal transducer and activator of transcription]] (STAT) proteins. These STAT proteins are then phosphorylated by JAK3, dimerize, and translocate to the [[cell nucleus]] where they act as transcription factors to modulate gene expression.


== Clinical Significance ==
== Clinical Significance ==
Mutations in the ''JAK3'' gene can lead to [[immunodeficiency]] syndromes, including [[severe combined immunodeficiency]] (SCID). Patients with JAK3-deficient SCID exhibit a lack of [[T cells]] and [[NK cells]], while [[B cells]] are present but functionally impaired. This condition is characterized by a severe impairment in both cellular and humoral immunity, leading to a high susceptibility to infections.
Mutations in the JAK3 gene can lead to severe combined immunodeficiency (SCID), a condition characterized by the absence of functional T and NK cells. JAK3 inhibitors are being explored as potential treatments for various autoimmune diseases and [[cancer]], due to their ability to modulate immune responses.


In addition to its role in immunodeficiency, JAK3 is a target for [[drug discovery]] due to its involvement in various autoimmune diseases and cancers. Inhibitors of JAK3, such as [[tofacitinib]], are being developed and used in the treatment of conditions like [[rheumatoid arthritis]], [[psoriasis]], and [[ulcerative colitis]].
== Related Pages ==
 
== Inhibitors ==
Several small molecule inhibitors targeting JAK3 have been identified and are in various stages of development and clinical trials for the treatment of autoimmune diseases and cancers. These inhibitors work by blocking the kinase activity of JAK3, thereby interrupting the JAK-STAT signaling pathway and reducing the inflammatory and proliferative responses.
 
== See Also ==
* [[Janus kinase]]
* [[Janus kinase]]
* [[JAK-STAT signaling pathway]]
* [[Signal transducer and activator of transcription]]
* [[Signal Transducer and Activator of Transcription]]
* [[Cytokine receptor]]
* [[Severe combined immunodeficiency]]
* [[Severe combined immunodeficiency]]
* [[Tofacitinib]]
== References ==
<references />


[[Category:Enzymes]]
[[Category:Signal transduction]]
[[Category:Signal transduction]]
[[Category:Tyrosine kinases]]
[[Category:Immune system]]
[[Category:Immunology]]
{{Medicine-stub}}

Latest revision as of 05:47, 16 February 2025


Janus Kinase 3[edit]

Diagram of JAK3 signal transduction pathway

Janus kinase 3 (JAK3) is a member of the Janus kinase family of intracellular, non-receptor tyrosine kinases. JAK3 is primarily expressed in hematopoietic cells and plays a crucial role in the signaling pathways of various cytokine receptors.

Structure[edit]

JAK3, like other members of the Janus kinase family, contains several important domains: a Ferm domain, an SH2-like domain, a pseudokinase domain, and a kinase domain. The kinase domain is responsible for the enzyme's catalytic activity, while the pseudokinase domain regulates the kinase activity.

Function[edit]

JAK3 is involved in the signaling of type I and type II cytokine receptors, which include receptors for interleukins such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. These cytokines are critical for the development and function of the immune system. JAK3 associates with the common gamma chain (_c) of these cytokine receptors and, upon cytokine binding, becomes activated through trans-phosphorylation.

Signal Transduction[edit]

Upon activation, JAK3 phosphorylates specific tyrosine residues on the receptor, creating docking sites for signal transducer and activator of transcription (STAT) proteins. These STAT proteins are then phosphorylated by JAK3, dimerize, and translocate to the cell nucleus where they act as transcription factors to modulate gene expression.

Clinical Significance[edit]

Mutations in the JAK3 gene can lead to severe combined immunodeficiency (SCID), a condition characterized by the absence of functional T and NK cells. JAK3 inhibitors are being explored as potential treatments for various autoimmune diseases and cancer, due to their ability to modulate immune responses.

Related Pages[edit]